文献速递血脂与心血管预防

Vupanorsen对接受他汀治疗且胆固醇升高患者非高密度脂蛋白胆固醇的影响:TRANSLATE-TIMI 70研究

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
PubMed 文献 · Circulation · 2022-04-03

结果显示Vupanorsen显著降低非HDL-C(22.0%-27.7%)和甘油三酯(41.3%-56.8%),但高剂量组注射部位反应和肝酶升高更常见,且肝脂肪分数呈剂量依赖性增加。

要点

  • Vupanorsen显著降低他汀治疗患者的非HDL-C和甘油三酯,呈剂量依赖性。
  • LDL-C和ApoB降幅较温和(7.9%-16.0%和6.0%-15.1%),仅较高剂量达统计学显著。
  • 高剂量组注射部位反应和肝酶升高更常见,肝脂肪分数剂量依赖性增加。

核心结论

  • Vupanorsen每月等效剂量80-320 mg可显著降低非HDL-C及其他血脂参数。
  • 高剂量时注射部位反应和肝酶升高更频繁,肝脂肪分数呈剂量依赖性增加。

研究设计与样本

  • 受试者随机分配至安慰剂组(44例)或7种Vupanorsen剂量方案组(242例),包括每4周80、120、160 mg或每2周60、80、120、160 mg皮下注射。
  • 主要终点为24周时非HDL-C相对基线的安慰剂校正百分比变化。

主要发现

  • 非HDL-C相对安慰剂显著降低,从每2周60 mg组的22.0%至每2周80 mg组的27.7%(所有剂量P<0.001)。
  • 甘油三酯呈剂量依赖性降低,幅度为41.3%至56.8%(所有P<0.001)。
  • LDL-C和ApoB降低幅度较温和,分别为7.9%-16.0%和6.0%-15.1%,无明确剂量反应关系,仅较高降幅达统计学显著。
  • ANGPTL3水平呈剂量依赖性降低69.9%至95.2%(所有P<0.001)。
  • 未确认Vupanorsen导致显著肾功能下降或血小板计数减少;高总月度剂量组注射部位反应和ALT/AST>3倍升高更常见(分别高达33.3%和44.4%),肝脂肪分数剂量依赖性增加(高达76%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. METHODS: Adults with non-high-density lipoprotein cholesterol (non-HDL-C) ≥100 mg/dL and triglycerides 150 to 500 mg/dL on statin therapy were randomized in a double-blind fashion to placebo or 1 of 7 vupanorsen dose regimens (80, 120, or 160 mg SC every 4 weeks, or 60, 80, 120, or 160 mg SC every 2 weeks). The primary end point was placebo-adjusted percentage change from baseline in non-HDL-C at 24 weeks. Secondary end points included placebo-adjusted percentage changes from baseline in triglycerides, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and ANGPTL3. RESULTS: Two hundred eighty-six subjects were randomized: 44 to placebo and 242 to vupanorsen. The median age was 64 (interquartile range, 58-69) years, 44% were female, the median non-HDL-C was 132.4 (interquartile range, 118.0-154.1) mg/dL, and the median triglycerides were 216.2 (interquartile range, 181.4-270.4) mg/dL. Vupanorsen resulted in significant decreases from baseline over placebo in non-HDL-C ranging from 22.0% in the 60 mg every 2 weeks arm to 27.7% in the 80 mg every 2 weeks arm (all P<0.001 for all doses). There were dose-dependent reductions in triglycerides that ranged from 41.3% to 56.8% (all P<0.001). The effects on LDL-C and ApoB were more modest (7.9%-16.0% and 6.0%-15.1%, respectively) and without a clear dose-response relationship' and only the higher reductions achieved statistical significance. ANGPTL3 levels were decreased in a dose-dependent manner by 69.9% to 95.2% (all P<0.001). There were no confirmed instances of significant decline in renal function or platelet count with vupanorsen. Injection site reactions and >3× elevations of alanine aminotransferase or aspartate aminotransferase were more common at higher total monthly doses (up to 33.3% and 44.4%, respectively), and there was a dose-dependent increase in hepatic fat fraction (up to 76%). CONCLUSIONS: Vupanorsen administered at monthly equivalent doses from 80 to 320 mg significantly reduced non-HDL-C and additional lipid parameters. Injection site reactions and liver enzyme elevations were more frequent at higher doses, and there was a dose-dependent increase in hepatic fat fraction. REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT04516291.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bergmark BA, Marston NA, Bramson CR, et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022. PMID: 35369705. doi:10.1161/CIRCULATIONAHA.122.059266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。